Pursuing Opportunity on the Edge of What is Known

We are applying our deep expertise in the biology of the body’s central mediators and internal pathways to build a biopharmaceutical company with a strong product pipeline, offering new approaches to the treatment of anemia, fibrosis, cancer, corneal blindness, and other serious medical conditions.

Our near- and long-term strategies include:

  • Advancing roxadustat through approval and commercial launch in collaboration with our pharmaceutical partners for treatment of anemia in chronic kidney disease (CKD).
  • Initiating roxadustat pivotal trials for treatment of anemia in myelodysplastic syndromes (MDS) in China, the U.S., and Europe.
  • Completing Phase 2 clinical studies of pamrevlumab in idiopathic pulmonary fibrosis and pancreatic cancer and advancing to Phase 3 pivotal studies for both indications.
  • Developing a proprietary biosynthetic cornea, FG-5200, for treatment of corneal blindness in China and elsewhere in the world.
  • Investing strategically in research and development to expand roxadustat into additional anemia indications and to expand pamrevlumab into additional fibrotic and proliferative diseases, such as Duchenne muscular dystrophy.
  • Maintaining an extensive and multi-layered patent portfolio to protect our technologies and product candidates.

FibroGen China

China is a critical part of FibroGen’s strategy and commitment to deliver groundbreaking therapies for serious diseases. FibroGen’s subsidiary in Beijing, FibroGen China, has manufacturing facilities in the Beijing Technology and Economic Development Agency outside of Beijing and office locations in Beijing, Shanghai, and Cangzhou, Hebei. We are committed to providing accelerated access to transformative medical treatment for patients in China. Furthermore, in parallel with our global program, we are developing roxadustat for anemia associated with CKD as a domestic Class 1 drug in China, and expect that China will become the first country in which roxadustat is approved.

FibroGen China

Learn about our Beijing subsidiary and our operations in China.